Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome
- 281 Downloads
To clarify the clinical impact of prior use of azacitidine (AZA) on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS), we retrospectively reviewed the clinical outcomes of 15 MDS patients who were treated with AZA before allo-HSCT (AZA group). We compared the outcomes of these 15 patients with 52 MDS patients who were solely given the best supportive care (BSC) before allo-HSCT (BSC group). Although patients in the AZA group were older with higher International Prognostic Scoring System (IPSS) scores compared to patients in the BSC group, no significant differences were found between the two groups in overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR) or non-relapse mortality. However, in patients with a higher IPSS score (Int-2/High), pre-transplant AZA may provide better OS and DFS and lower CIR. Acute graft-versus-host disease rates were similar between the two groups. These results should be reassuring to patients with high-risk MDS receiving AZA before allo-HSCT.
KeywordsMyelodysplastic syndrome Allogeneic hematopoietic stem cell transplantation Azacitidine
We thank all of the physicians and nurses who cared for patients in this study.
Conflicts of interest
The authors declare no conflicts of interest.
- 3.Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedCentralCrossRefPubMedGoogle Scholar
- 5.Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M et al (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 20:4533–4540CrossRefGoogle Scholar
- 16.NCCN (2012) Clinical practice guidelines in oncology: Myelodysplastic syndromes version 2.2014. National Comprehensive Cancer Network, WashingtonGoogle Scholar